The anti-diabetic drug repaglinide induces vasorelaxation via activation of PKA and PKG in aortic smooth muscle

Antidiabetic omarigliptin dilates rabbit aorta by activating voltage-dependent K+ channels and the sarco/endoplasmic reticulum Ca2+ -ATPase pump

We investigated the vasodilatory effect of omarigliptin, an oral antidiabetic drug in the dipeptidyl peptidase-4 inhibitor class, and its related mechanisms using phenylephrine (Phe)-induced pre-contracted aortic rings. Omarigliptin dilated aortic rings pre-constricted with Phe in a dose-dependent manner. Pretreatment with the voltage-dependent K⁺ channel inhibitor 4-aminopyridine significantly attenuated the vasodilatory effect of omarigliptin, whereas pretreatment with the inwardly rectifying K⁺ channel inhibitor Ba²⁺ , ATP-sensitive K⁺ channel inhibitor glibenclamide, and large-conductance Ca²⁺ -activated K⁺ channel inhibitor paxilline did not alter its vasodilation. Pretreatment with the sarco/endoplasmic reticulum Ca²⁺ -ATPase (SERCA) pump inhibitors thapsigargin and cyclopiazonic acid significantly reduced the vasodilatory effect of omarigliptin. Neither cAMP/PKA-related signaling pathway inhibitors nor cGMP/PKG-related signaling pathway inhibitors modulated the vasodilatory effect of omarigliptin. Removal of endothelium did not diminish the vasodilatory effect of omarigliptin. Furthermore, pretreatment with the nitric oxide synthase inhibitor L-NAME or small-conductance Ca²⁺ -activated K⁺ channel inhibitor apamin, together with the intermediate-conductance Ca²⁺ -activated K⁺ channel inhibitor TRAM-34, did not influence the vasodilatory effect of omarigliptin. In conclusion, omarigliptin induced vasodilation in rabbit aortic smooth muscle by activating voltage-dependent K⁺ channels and the SERCA pump independently of other K⁺ channels, cAMP/PKA- and cGMP/PKG-related signaling pathways, and the endothelium.

Mechanisms underlying the vasodilatory effects of canagliflozin in the rabbit thoracic aorta: Involvement of the SERCA pump and Kv channels

AIMS

Canagliflozin is an anti-diabetic agent and sodium glucose co-transporter-2 inhibitor. Despite numerous clinical trials demonstrating its beneficial effects on blood pressure, the cellular mechanisms underlying the effects of canagliflozin on vascular reactivity have yet to be clarified. We investigated the vasodilatory effect of canagliflozin on aortic rings isolated from rabbits.

MAIN METHODS

We used rabbit thoracic aortic rings and its arterial tone was tested by using wire myography system.

KEY FINDINGS

Canagliflozin caused concentration-dependent vasodilation in aortic rings pre-constricted with phenylephrine or high K⁺. However, the degree of canagliflozin-induced vasodilation of the aortic rings pre-constricted with high K⁺ was less than that of rings pre-constricted with phenylephrine. Application of 4-aminopyridine, a voltage-dependent K⁺ (Kv) channel inhibitor, reduced canagliflozin-induced vasodilation. However, pre-incubation of an inwardly rectifying K⁺ channel inhibitor, a large-conductance Ca²⁺-activated K⁺ channel inhibitor, and an ATP-sensitive K⁺ inhibitor did not modulate the vasodilatory effects of canagliflozin. Indeed, canagliflozin increased Kv currents in aortic smooth muscle cells. Pre-treatment with thapsigargin or cyclopiazonic acid, a sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) pump inhibitors, reduced the vasodilatory effects of canagliflozin. Conversely, pre-treatment with a Ca²⁺ channel inhibitor, adenylyl cyclase/PKA inhibitors, and guanylyl cyclase/PKG inhibitors did not modulate the vasodilatory effects of canagliflozin. Endothelium removal, and pre-treatment with the nitric oxide synthase inhibitor L-NAME, and small- and intermediate-conductance Ca²⁺-activated K⁺ channel inhibitor apamin and TRAM-34, did not diminish the vasodilatory effects of canagliflozin.

SIGNIFICANCE

Our results indicate that canagliflozin induces vasodilation, which is dependent on the robust SERCA activity and Kv channel activation.

Dipeptidyl peptidase-4 inhibitor sitagliptin induces vasorelaxation via the activation of Kv channels and PKA

The present study investigated the vasorelaxant effects of sitagliptin, which is a dipeptidyl peptidase-4 (DPP-4) inhibitor in aortic rings pre-contracted with phenylephrine (Phe). Sitagliptin induced vasorelaxation in a concentration-dependent manner but the inhibition of voltage-dependent K⁺ (Kv) channels by pretreatment with 4-aminopyridine (4-AP) effectively reduced this effect. By contrast, the inhibition of inward rectifier K⁺ (Kir) channels by pretreatment with barium (Ba²⁺), large-conductance calcium (Ca²⁺)-activated K⁺ (BK_Ca) channels with paxilline, and adenosine triphosphate (ATP)-sensitive K⁺ (K_ATP) channels with glibenclamide did not change this effect. Although the application of SQ 22536, which is an adenylyl cyclase inhibitor, also did not change this effect, treatment with KT 5720, a protein kinase A (PKA) inhibitor, effectively reduced the vasorelaxant effects of sitagliptin. ODQ, which is a guanylyl cyclase inhibitor, and KT 5823, a protein kinase G (PKG) inhibitor, did not impact the effect. Furthermore, neither the inhibition of Ca²⁺ channels by pretreatment with nifedipine nor the inhibition of sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase (SERCA) pumps by pretreatment with thapsigargin changed the effect. Similarly, the effects of sitagliptin were not altered by eliminating the endothelium, by pretreatment with a nitric oxide (NO) synthase inhibitor (L-NAME), or by inhibition of small- and intermediate-conductance Ca²⁺-activated K⁺ channels (SK_Ca and IK_Ca) using apamin and TRAM-34. Taken together, these results suggest that sitagliptin induces vasorelaxation by inhibiting both membrane potential (Em)-dependent and -independent vasoconstriction and activating PKA and Kv channels independently of PKG signaling pathways, other K⁺ channels, SERCA pumps, and the endothelium.

The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels

AIM

Considering the clinical efficacy of dapagliflozin in patients with type 2 DM and the pathophysiological relevance of Kv channels for vascular reactivity. We investigate the vasodilatory effect of dapagliflozin and related mechanisms using phenylephrine (Phe)-induced contracted aortic rings.

MATERIAL AND METHODS

Arterial tone measurement was performed in aortic smooth muscle.

KEY FINDINGS

Application of dapagliflozin induced vasodilation in a concentration-dependent manner. Pre-treatment with the BK_Ca channel inhibitor paxilline, the K_ATP channel inhibitor glibenclamide, and the Kir channel inhibitor Ba²⁺ did not change dapagliflozin-induced vasodilation. However, application of the Kv channels inhibitor 4-AP effectively inhibited dapagliflozin-induced vasodilation. Application of the Ca²⁺ channel inhibitor nifedipine and the sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase (SERCA) pump inhibitor thapsigargin did not alter the vasodilatory effect of dapagliflozin. Moreover, the adenylyl cyclase inhibitor SQ 22536 and the protein kinase A (PKA) inhibitor KT 5720 had no effect on dapagliflozin-induced vasodilation. Although guanylyl cyclase inhibitors, NS 2028 and ODQ, did not reduce the vasodilatory effect of dapagliflozin, the protein kinase G (PKG) inhibitor KT 5823 effectively inhibited dapagliflozin-induced vasodilation. The vasodilatory effect of dapagliflozin was not affected by elimination of the endothelium. Furthermore, pretreatment with the nitric oxide synthase inhibitor L-NAME or the small-conductance Ca²⁺-activated K (SKCa) channel inhibitor apamin did not change the vasodilatory effect of dapagliflozin.

SIGNIFICANCE

We concluded that dapagliflozin induced vasodilation via the activation of Kv channels and PKG, and was independent of other K⁺ channels, Ca²⁺ channels, intracellular Ca²⁺, and the endothelium.

The vasorelaxant effect of mitiglinide via activation of voltage-dependent K+ channels and SERCA pump in aortic smooth muscle

AIMS

The vasorelaxant effects of the anti-diabetic drug, mitiglinide in phenylephrine (Phe)-pre-contracted aortic rings were examined.

MATERIALS AND METHODS

Arterial tone measurement was performed in aortic smooth muscle cells.

KEY FINDINGS

Mitiglinide dose-dependently induced vasorelaxation. Application of the large-conductance Ca²⁺-activated K⁺ (BK_Ca) channel blocker paxilline, inwardly rectifying K⁺ (Kir) channel blocker Ba²⁺, and ATP-sensitive K⁺ (K_ATP) channel blocker glibenclamide did not affect the vasorelaxant effect of mitiglinide. However, application of the voltage-dependent K⁺ (Kv) channel blocker 4-AP, effectively inhibited mitiglinide-induced vasorelaxation. Although pretreatment with the Ca²⁺ channel blocker nifedipine did not alter the mitiglinide-induced vasorelaxation, pretreatment with the sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase (SERCA) pump inhibitor thapsigargin and cyclopiazonic acid reduced the vasorelaxant effect of mitiglinide. In addition, the vasorelaxant effect of mitiglinide was not affected by the inhibitors of adenylyl cyclase, protein kinase A, guanylyl cyclase, or protein kinase G. Elimination of the endothelium and inhibition of endothelium-dependent vasorelaxant mechanisms also did not change the vasorelaxant effect of mitiglinide.

SIGNIFICANCE

We proposed that mitiglinide induces vasorelaxation via activation of Kv channels and SERCA pump. However, the vasorelaxant effects of mitiglinide did not involve other K⁺ channels, Ca²⁺ channels, PKA/PKG signaling pathways, or the endothelium.